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Background: Developmental haemostatic studies may help identifying new elements involved in the control of
key haemostatic proteins like antithrombin, the most relevant endogenous anticoagulant.
Results: In this study, we showed a significant reduction of sialic acid content in neonatal antithrombin compared
with adult antithrombin in mice. mRNA levels of St3gal3 and St3gal4, two sialyltransferases potentially involved in
antithrombin sialylation, were 85% lower in neonates in comparison with adults. In silico analysis of miRNAs
overexpressed in neonates revealed that mir-200a might target these sialyltransferases. Moreover, in vitro studies in
murine primary hepatocytes sustain this potential control.
Conclusions: These data suggest that in addition to the direct protein regulation, microRNAs may also modulate
qualitative traits of selected proteins by an indirect control of post-translational processes.
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MicroRNAs (miRNAs) are small non-coding RNAs impli-
cated in the modulation of a large number of physiological
and pathological processes [1,2] through a mechanism
based on the repression of protein translation or degrad-
ation of messenger RNAs [3]. MiRNAs have been recently
involved in the modulation of several haemostatic factors
such as fibrinogen, tissue factor, and proteins implicated
in platelet function [4-6]. Actually, miRNAs can also be
involved in the quantitative variations of elements of the
haemostatic system observed during development [7]. In
humans, levels of haemostatic factors go in constant in-
crease after birth until reaching levels similar to those
found in adults within the first year [8-10]. In particular,
antithrombin, an anticoagulant serpin crucial in the con-
trol of the hemostatic system [11], is significantly reduced
(50%) in plasma of neonates in comparison with adults* Correspondence: constant@um.es
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reproduction in any medium, provided the or[8]. Despite these differences, neonates maintain a perfect
haemostatic equilibrium. Accordingly, a developmental
model between neonatal and adult period is ideal to study
the mechanisms that regulate haemostatic protein levels
and the adaptation of this system to particular conditions.
In addition to these quantitative changes, few works have
shown that neonatal antithrombin has lower levels of si-
alic acid than its adult counterpart but the molecular
mechanism of this regulation is unknown [12,13]. Thus,
the developmental model may also allow to investigating
the regulation of N-glycosylation by miRNAs and thus to
further enlarge the effects of miRNAs in gene regulation.Methods
Mouse samples
Non-inbred Swiss CD1 mice from different litters were
sacrificed by cervical dislocation or decapitation at differ-
ent ages, from day one after birth to adult age. Livers
finely dissected were immediately snap-frozen in liquid
nitrogen. Blood was anticoagulated with trisodium citrate,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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poor plasma and immediately stored in aliquots at −80°C.
All experimental procedures strictly followed the Univer-
sity of Murcia approved Institutional Animal Care guide-
lines and were approved by the local ethical committee
(#C131002043; 15/02/2010).
Antithrombin levels and activity
Antithrombin activity was determined by chromogenic
methods, as previously described [14]. Anti-factor Xa (anti-
FXa) assay was performed with pentasaccharide, bovine FXa,
and S-2765 chromogenic substrate (Chromogenix, IZASA,
Spain). Antithrombin levels were determined by enzyme-
linked immunosorbent assay and electro-immunodiffusion
(Laurell), as previously reported [15]. Values were expressed
as a percentage relative to a pool of citrated plasma from 10
adult control mice (100%).
Electrophoretic analysis of antithrombin
Mouse plasma samples were run in polyacrylamide gel
electrophoresis under denaturing and non-denaturing
conditions, blotted onto PVDF membranes, and immuno-
detected with goat anti-human antithrombin polyclonal
antibody (Sigma-Aldrich, Madrid, Spain) and rabbit
anti-goat IgG-horseradish peroxidase conjugate (Sigma-
Aldrich, Madrid, Spain), with detection via an ECL kit
(Amersham Biosciences, Little Chalfont, UK), essentially
as described elsewhere [16].
Isoelectrofocusing
Plasma samples from adult and neonate mice were subjected
to isoelectrofocusing (IEF) analysis and electroelution using
an OFFGEL fractionator with strips of 12 cm with a pH
gradient of 4–7 (Agilent 3100, Agilent Technologies,Madrid,
Spain). Each fraction collected was run in SDS-PAGE gel
and immunodetected as described above.
Glycosylation analysis
Plasma from adult and neonate (+1 day) mice (10 μL)
were treated with 2 U α2-3,6,8,9 neuraminidase (sialidase)
(N 3786, Sigma-Aldrich, Saint Louis, USA) at 37°C for 18
hours in 50 mM sodium phosphate buffer, pH 6.0. Sam-
ples were resolved by SDS-PAGE and detected as previ-
ously described.
RNA Isolation
Total RNA was isolated from frozen liver using Trizol®
Reagent (Invitrogen, Carlsbad, CA) following manufac-
turer’s instructions. The RNA concentration and 260/
280 ratio were determined by using NanoDrop spectro-
photometer (Thermo Scientific, Wilmington, DE) and
RNA integrity was verified by lab-on-chip technology
using the Experion automated electrophoresis system
(Bio-Rad Laboratories, Madrid, Spain).MicroRNA microarray
MicroRNAs microarray profiling was performed using
total RNA extracted from the liver from one adult mouse
(day +50) and one neonate mouse (day +1) using the LC
Sciences technology (LC Sciences, Houston, TX). The
arrays were designed to detect and quantify miRNA tran-
scripts corresponding to 558 mature miRNAs contained
in the Sanger mirBase Release 10.0 (miRMouse 10.0: ftp://
mirbase.org/pub/mirbase/10.0/). We used two chips (1
and 2) in which RNAs from each sample were labeled ei-
ther with cy3 or with cy5. The signal values were derived
by background subtraction and normalization. Additional
details on the array are available elsewhere [7].
In silico studies
Several web databases and algorithms of miRNA target
prediction were used for the search of miRNA targeting
sialyltransferases. We essentially used TargetScan [17] (re-
lease 5.1: http://www.targetscan.org), which provides
the prediction results computed by the TargetScanS algo-
rithm, PicTar (http://pictar.mdc-berlin.de) [18], and mi-
Randa (http://www.microrna.org/microrna/home.do) [19].
Murine hepatocyte primary culture
Hepatocytes were isolated from livers of Swiss CD1 mice
using a modified version protocol from Wu et al. [20].
Mice were anesthetized with an intraperitoneal injection
of a ketamine/xylazine mixture. A 24G clear cannula
was inserted into the posterior vena cava and secured
with a ligature. A second ligature was placed around the
anterior vena cava, between the liver and the heart, and
the portal vein was severed, allowing outflow of solution.
The liver was then perfused at 37°C with oxygenized
HBSS (in mM: 137 NaCl, 5.4 KCl, 0.8 MgSO4.7H2O, 0.3
NaHPO4.2H2O, 0.44 KH2PO4, 26 NaHCO3, pH 7.4)
3 min at 5 mL/min and 5 min at 7 mL/min. The perfu-
sion solution was then changed to HBSS supplemented
with 4 mM CaCl2 and containing 0.12% collagenase
(Sigma-Aldrich, Madrid, Spain) for 8 min at 5 mL/min.
The liver was additionally incubated with HBSS with
0.12% collagenase for 15 min, filtered through a cell
strainer (100 μm from Becton Dickinson, Madrid, Spain)
and hepatocytes were isolated by repeated 50 × g centri-
fugations. Viability was assessed using trypan blue to be
>90% in all the cases. Six-well plates were pre-coated with
50 μg/mL collagen from Stemcell (Grenoble, France) for
12 h at 4°C and cells were seeded at 250,000/well.
Hepatocyte transfection
Primary hepatocytes were maintained in DMEM/F12
supplemented with 10% fetal bovine serum at 37°C in a
humidified incubator with 5% CO2. Cells were pre-
cultured for 24 h in complete medium without anti-
biotics and transfected at 40-60% confluence with 100
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and negative scrambled control (Applied Biosystems,
Madrid, Spain) by using siPORT™NeoFX™ transfection agent
(Applied Biosystems, Madrid, Spain). The cells were collected
48 hours after transfection and total RNAwas extracted.
qRT-PCR and validation assays
Total RNA from mouse livers and from transfected hepato-
cytes was isolated using Trizol® Reagent (Invitrogen, Madrid,
Spain). RNA integrity was verified using bioanalyzer (Bio-
Rad, Madrid, Spain). RNA samples were stored at −80°C
until used in the experiments. ThemiRNA andmRNAquan-
tification were carried out as previously described [5]. For
St3gal3, St3gal4, and St6gal1, as well as for serpinc1 tran-
scripts relative quantification, retrotranscription reactions
were performed using 100 ng of total RNA for each sample
according to the manufacturer instructions (SuperScript
First Strand, Invitrogen, Madrid, Spain). One set of primers
and a probe were chosen from the Applied Biosystems list of
TaqMan® Gene Expression Assays for these sialyltransferases
(Hs00544033_m1, Hs00920871_m1, and Hs00949382_m1,
respectively). For serpinc1 expression was measured using
assay Hs00166654_m1 (Applied Biosystems). SialyltransferaseFigure 1 Expression of antithrombin in neonate and adult mice. Leve
(day +50, n=6) mice: (A) plasma antigen, (B) plasma anti-FXa activity, and (
plasma anti-factor Xa activity at different stages of development relative to
Student's t test taking the adult group as a reference group. Statistical sign
significant. *Anti-FXa activity was statistically significant.mRNA expression analysis was performed in triplicate for
each sample. Expression of β-actin (Hs99999903_m1) was
used as endogenous reference control. The PCR reactions
were performed using an LC480 Real Time PCR system
(Roche Applied Science, Barcelona, Spain). We employed
the 2-ΔCt method to calculate the relative abundance of
miRNA and mRNA compared with endogenous control
expression. Ct is the Threshold Cycle and ΔCt = Ct sam-
ple gene - Ct endogenous control.
MiRNA assay kits for miR-200a (Applied Biosystems,
Madrid, Spain) were used to validate expression levels in
mouse hepatocytes during post-natal development (neo-
nates day+1, n=14; adults day+50, n=5). Expression of U6
snRNA (Applied Biosystems, Madrid, Spain) was used as
endogenous reference control.
Results
Quantitative differences of antithrombin between
neonate and adult mice
Antithrombin levels in plasma of neonates (day+1) were
60% lower than in adults (day+50) [36±4% (n=13) vs.
86±7% (n=6)] (Figure 1A). As expected, correlating values
were observed in antithrombin activity [neonate (n=13):ls of antithrombin in neonate (day +1, n=13) relative to adult
C) serpinc1 mRNA. (D) Levels of plasma antithrombin antigen and
adult stage (n=5 for each age). Differences were analyzed by means of
ificance was taken as p<0.05. **Both measurements were statistically
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the association between these values and serpinc1 mRNA
levels in liver. As shown in Figure 1C, serpinc1mRNA levels
in neonates and adults [36±5% (n=13) vs. 100±9% (n=6)]
matched with previously published data [7], and correlated
with antigen and functional levels in plasma. In order to bet-
ter delineate the variations observed along the development,
we determined the antigenic levels and activity of antithrom-
bin of three different mice litters from day one after birth to
adult age. Our results showed that antithrombin antigen and
activity levels paralleled. At day+13 after birth, antithrombin
levels were similar to those observed in adults (Figure 1D).
Qualitative differences of antithrombin in neonate and
adult mice
SDS-PAGE analysis of plasma antithrombin revealed that
plasma antithrombin from neonate mice had a lowerFigure 2 Electrophoretic features of plasma antithrombin in neonate
mice at different stages of development (the number indicates the age in
native (B) conditions. In order to check for potential biases under native co
contained 3 μL (3x) of neonate (day +1) plasma and 0.3 μL (1/3) of adult (d
isoelectrofocusing and electroelution of plasma antithrombin from neonate
representative of different experiments (A, B, and C: n=3; D: n=2).molecular weight than its adult counterpart (Figure 2A).
We next performed native gel electrophoresis with plasma
samples extracted at different times during mouse post-
natal development. Newborn mice had a plasma anti-
thrombin with slower migration than the adult one
(Figure 2B), and this result is compatible with a lower
global negative charge in neonate’s antithrombin. Plasma
antithrombin concentration was not responsible for the
differences in electrophoretic mobility (Figure 2B, last
lanes). Interestingly, we observed that at day+15, plasma
antithrombin from neonate had the same electrophoretic
characteristics (Figure 2B) and size (Figure 2C) than adult
antithrombin.
To further evaluate the differences of neonatal and
adult antithrombins, we performed IEF of plasma from
neonate and adult mice. Our results showed that neo-
nates expressed more antithrombin isoforms with higherand adult mice during post-natal development. Plasma (1 μL) from
days) were evaluated in PAGE gels under SDS denaturing (A, C) or
nditions due to antithrombin loading charge, the two last lanes
ay +50) plasma. (D) SDS-PAGE of selected fractions obtained after
and adult mice [Isoelectric point (pI) values are indicated]. Images are
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(Figure 2D). These results were in accord with those
obtained in native electrophoresis.Antithrombin glycosylation
In order to evaluate the role of glycosylation in the
qualitative changes of neonate’s antithrombin, we treated
plasma from adult and neonate mice with neuramini-
dase. This treatment rendered the same electrophoretic
mobility in SDS-PAGE gels for adult’s and neonate’s
antithrombins and sustained an incomplete content of
sialic acid for neonate’s antithrombin (Figure 3) that may
explain the different migration of neonate’s antithrombin
observed in SDS, native electrophoresis, as well as the
IEF results (Figure 2).Expression of sialyltransferases potentially involved in
glycosylation of antithrombin
There are three different sialyltransferases able to sialylate
N-linked glycoproteins like antithrombin, i.e. St3gal-III,
St3gal-IV, and St6gal-I. In order to evaluate if any of these
three sialyltransferases were down regulated in neonates,
we measured their mRNA levels in liver from neonates
and adults by qRT-PCR. As shown in Figure 4, our results
indicated an ~85% reduction in neonates in comparison
with adults for St3gal3 and St3gal4 expression, whereas
levels of St6gal1 mRNA remained unchanged. As it hap-
pened for antithrombin, mRNA levels of St3gal3 and
St3gal4 were similar to those observed in adults at day+13
after birth (Figure 4).Figure 3 Glycosylation of antithrombin from neonate (day +1)
and adult (day +50) mice. The image, representative of two
different experiments, shows the electrophoretic pattern of plasma
antithrombin treated or not with neuraminidase (Neu).Regulation of St3gal3 and St3gal4 by miR-200a
One hypothesis to explain the variation of the levels of
St3gal3 and St3gal4 during post-natal development may
reside in a miRNA-dependent regulation. Using target
predicting algorithms, we found that miR-200a may
target St3gal3 and St3gal4 (Table 1) and thus it was a
valuable candidate to explain the lower sialylation of
antithrombin in neonate mice. Interestingly, the analysis
of the subtractive miRNA array revealed that miR-200a
is over-expressed in neonates in comparison with adults
in both chips. Moreover, validation studies in 5 adults
and 14 neonates by qRT-PCR confirmed this result
(Figure 5A). The next step to demonstrate the potential
regulation of St3gal3 and St3gal4 by miR-200a was to
perform transfection studies of primary hepatocytes
from adult mouse with miR-200a. Interestingly, this
procedure provoked a significant reduction of St3gal3
and St3gal4 (31% and 20%, respectively), whereas no
effect was observed when a scrambled oligonucleotide
was employed or when cells were transfected with miR-
17-3p, a miRNA expressed at high levels in neonates
that, according to in silico predictions, does not modu-
late these sialyltransferases (Figure 5B).
Discussion
Antithrombin is the main endogenous anticoagulant
and, thus, its role in regulating haemostasis is absolutely
essential. Indeed, complete antithrombin deficiency is in-
compatible with life and partial deficiency is an import-
ant risk factor for developing venous thrombosis [21].
Besides its role in haemostasis, antithrombin may also
regulate other important physiological processes such as
inflammation, angiogenesis or apoptosis [22-24]. Intri-
guingly, the levels of antithrombin in neonates are severely
reduced in comparison with adults without relevant
physiological consequences [8,9,25]. This study confirms
that the difference not only relies on protein expression
levels but also in post-translational modifications. Here,
we studied the expression, features, and functionality of
antithrombin in a mouse model to deepen into the impact
of post-translational modifications of this protein in devel-
opmental haemostasis.
Our previous results suggested that the lower levels of
antithrombin in neonate mice are mainly explained by a
concomitant reduction of mRNA in hepatocytes [7]. In
addition, electrophoretic data in the present study sug-
gest that the lower molecular weight of antithrombin
from neonates is due to a post-translational modifica-
tion: an abnormal N-glycosylation (Figures 2 and 3). Our
results show that the sialic acid content of antithrombin
is smaller in neonates than adults. Unfortunately, we
were unable to perform fine glycomic studies to calculate
the exact sialic acid content of neonate antithrombin due
Figure 4 Levels of selected sialyltransferases mRNA and of miR-200a in neonate and adult liver. Levels of mRNA from three
sialyltransferases (St3gal3 and St3gal4, and St6gal1) at different stages of development relative to adult stage (n=5 for each age) were measured
by qRT-PCR and normalized with respect to β-actin mRNA.
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this procedure. Interestingly, a reduced sialylation of anti-
thrombin has also been described for antithrombin in
chicken and sheep neonates [12,13]. These data strongly
suggest that this has to be a process highly regulated in
different species. Aiming to identify the mechanisms
involved in such control, we evaluated the mRNA levels of
three sialyltransferases potentially involved: St3gal3,
St3gal4, and St6gal1. Indeed, St6gal-I performs α2-6 sialic
acid linkage as that present in antithrombin [26]. Accor-
dingly, this enzyme seems to be the main responsible for
the sialylation of antithrombin. However, in St6gal-I KO
mice, St3gal-IV, that performs α2-3 linkages, may also
achieve α2-6 linkages in von Willebrand factor [27]. In
addition, a study by Fan et al. revealed that recombinant
human antithrombin expressed in baby hamster kidney
cells is fully sialylated containing α2-3 linkage [28]. Thus,
it is worth suggesting that the lower levels of sialic acid in
neonate’s antithrombin might be explained by the reducedTable 1 miR-200a putative target site in St3gal3 and St3gal4
miRNA target prediction software Parameters
TargetScan (release 5.2) [17] Seed match
Context score pe
PCT
Pictar [18] Score
Target site numb
Free energy (Kca
microRNA.org [19] mirSVR score
PhastCons scoreexpression of St3gal3 and St3gal4. Further experiments
are necessary to clarify these issues.
The next step to understand the mechanism respon-
sible for these differences was the identification of the
element(s) controlling the levels of these sialyltransferases. In
this framework, the recent report suggesting that some con-
served genes implicated in glycosylation pathwaymay be reg-
ulated by miRNAs during animal development [29], reveals
miRNAs as potential candidates. n fact, in silico searching
identified miR-200a as an excellent regulator of St3gal3 and
St3gal4. Interestingly, the levels of this miRNA during deve-
lopment show a fully compatible change (overexpressed in
neonate mice, but reduced expression in adults). The final
proof indicating the control of these sialyltransferases by
miR-200a was obtained by transfecting this miRNA in adult
primary hepatocytes. These experiments suggest that miR-
200a may be in part implicated in the regulation of St3gal3
and, in a lesser degree, in the regulation of St3gal4, as pre-
dicted by in silico studies (Table 1). Specificity of thismRNA using different target prediction software
St3gal3 St3gal4
7mer-m8 7mer-m8
rcentile 85 75
0.35 0.17
4.67 -
er 1 -
l/mol) −21.4 -
−0.9262 −0.2421
0.5877 0.5271
Figure 5 Role of miR-200a in the control of St3gal3 and St3gal4 in murine primary hepatocytes. (A) Fold increase of miR-200a in neonate
vs. adult liver was determined in a miRNA array (chip 1 and chip 2) and validated by qRT-PCR in livers from 5 adult and 14 neonate mice.
(B) Primary hepatocytes from adult mice were transfected with precursor molecules for miR-200a and miR-17-3p and with a scrambled
oligonucleotide at 100 nmol/L. After 48 h, total RNA was purified and levels of St3gal3 and St3gal4 were measured by qRT-PCR and normalized
with respect to β-actin mRNA. The normalized data were expressed as changes relative to the data of the cells transfected with scrambled pre-
miR and set as 100%. Differences were analyzed by means of Student's t test. Statistical significance was taken as *p<0.05, **p<0.01, NS: not
statistically significant. The data shown are expressed as mean ± SD, representative of four independent experiments with three replicates each.
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miRNA overexpressed in neonate’s liver, miR-17-3p. How-
ever, other mechanisms and additional miRNAs still to
characterize may be involved in the reduced expression of
these two sialyltransferases in neonatemice.
Finally, it would be of great interest to evaluate whether
or not these qualitative modifications regulated indirectly
by miRNAs could have functional significance apart of
contributing to an increased clearance [30]. In our case, it
is necessary to investigate the functional relevance of the
lower sialylation in antithrombin, not only on the anti-
coagulant function, which might contribute to explain the
dramatic change of the haemostatic system after birth, but
also on other functions of this molecule.Conclusions
Our results supported by those of Kahai et al. showing
that UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 7 (GalNAc-T7) is inhibited
by miR-378 with consequences in the rate of osteoblast
differentiation [31], open new and interesting perspec-
tives, as the regulation of proteins involved in N-glyco-
sylation (and potentially any other post-translational
modification) of antithrombin (and extensively other
proteins) may be done by miRNAs. The role of miRNAs
in diseases and physiological processes is therefore not
restricted to the direct control of proteins of one system
(in this case, the haemostatic system), but could be
extended to an indirect effect by affecting elements
Teruel et al. Journal of Biomedical Science 2013, 20:29 Page 8 of 8
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translational processes.
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